[1]
|
陆赛花,吴玮峰,刘秀凤,等.临床药师在呼吸科参与抗菌药物使用的体会[J].中国医院药学杂志,2012,32(8):645-646. |
[2]
|
李雪芹,李云景,卢荣枝,等.临床药师参与317例细菌感染性病例会诊分析[J].中国药物应用与监测,2012,9(3):150-152. |
[3]
|
张波,冯雷,梅丹. 临床药师参与会诊的实践和分析[J].中国医院药学杂志,2014,34(2):148-151. |
[4]
|
Quantrill S, Webbe D. Including pharmacists on consultant-led ward rounds[J]. Clin Med, 2011,11(6):627-628. |
[5]
|
丁伯君,邓艳春,文娟.左乙拉西坦添加治疗难治性癫痫的疗效和安全性分析[J].中国临床神经科学,2011,19(2):189-191,198. |
[6]
|
袁展望,李武平,刘冰,等.预防留置导尿管相关感染研究进展[J]. 中国感染控制杂志,2013,12(5):397-399. |
[7]
|
陈晓华,李武平,刘冰,等.泌尿系统感染现状及防治研究进展[J].解放军护理杂志,2015,32(16):38-42,45. |
[8]
|
Sarmiento JM, Dockrell DH, Schwab TR,et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients[J]. Clin Transplant, 2000,14(2):136-138. |
[9]
|
Kupeli E, Ulubay G, Golak T, et al. Pulmonary complications in renal recipients after transplantation[J]. Transplant Proc,2011,43(2):551-553. |
[10]
|
孙斌,汪泽厚,姚志勇,等. 肾移植术后肺部感染患者免疫抑制剂的调整[J]. 空军总医院学报,2007,23(3):152-156. |
[11]
|
Nose K, Oki T, Banno E, et al. Cytomegalovirus infection after prophylactic valganciclovir therapy postkidney transplantation:case reports[J]. Transplant Proc,2012,44(1):296-298. |
[12]
|
Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation[J]. Transpl Infect Dis,2011,13(6):551-558. |
[13]
|
Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation:current epidemiology and associated risk factors[J]. Clin Transplant, 2006,20(4):401-409. |
[14]
|
Dantas SR, Kuboyama RH, Mazzali M, et al. Nosocomial infections in renal transplant patients:risk factors and treatment implications associated with urinary tract and surgical site infections[J]. J Hosp Infect, 2006, 63(2):117-123. |
[15]
|
Rubin RH, Wolfson JS, Cosimi AB, et al. Infection in the renal transplant recipient[J]. Am J Med,1981,70(2):405-411. |
[16]
|
郭代红,陈超,李罄,等. 6所医院414例利奈唑胺相关性血小板减少集中监测研究[J].药物流行病学杂志,2013,22(3):109-113. |
[17]
|
Chen C, Guo DH, Cao XT, et al. Risk factors for thrombocytopenia in adult Chinese receiving linezolid therapy[J]. Curr Ther Res Clin Exp, 2012,73(6):195-206. |
[18]
|
Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia[J].Int J Antimicrob Agents,2009,36(2):179-181. |
[19]
|
Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction[J]. Int J Antimrcro Agents,2009,33(1):98-99. |
[20]
|
Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction[J]. Antimicrob Agents Chemother, 2003,47(9):2775-2780. |